These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 35769314)

  • 1. Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.
    Razonable RR; Ganesh R; Bishop RK; Culbertson TL; Destro Borgen M; Hedin MC; Hopkins LH; Jackson TA; Larsen JJ; Matoush JA; Moehnke DE; Olson SM; Peterson KM; Rosedahl J; Philpot LM
    J Patient Exp; 2022; 9():23743735221105673. PubMed ID: 35769314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
    Bierle DM; Ganesh R; Wilker CG; Hanson SN; Moehnke DE; Jackson TA; Ramar P; Rosedahl JK; Philpot LM; Razonable RR
    J Prim Care Community Health; 2021; 12():21501327211019282. PubMed ID: 34032171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
    Tulledge-Scheitel S; Bell SJ; Larsen JJ; Bierle DM; Takahashi P; Moehnke DE; Destro Borgen MJ; Springer DJ; Reinschmidt KJ; Baumbach LJ; Matoush JA; Heyliger A; Hanson SN; Razonable RR; Ganesh R
    J Am Geriatr Soc; 2021 Apr; 69(4):868-873. PubMed ID: 33619724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience.
    Chilimuri S; Mantri N; Gurjar H; Youthjug KA; Sun H; Gongati S; Zahid M; Ronderos DM; De La Cruz A; Varanasi P; Shin D; Nayudu SK
    J Natl Med Assoc; 2022 Jan; 113(6):701-705. PubMed ID: 34521513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
    San Filippo S; Crovetto B; Bucek J; Nahass RG; Milano M; Brunetti L
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac080. PubMed ID: 35299987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
    Koehler J; Ritzer B; Weidlich S; Gebhardt F; Kirchhoff C; Gempt J; Querbach C; Hoffmann D; Haller B; Schmid RM; Schneider J; Spinner CD; Iakoubov R
    Infection; 2021 Dec; 49(6):1313-1318. PubMed ID: 34244967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
    Dale AP; Hudson MJ; Armenta D; Friebus H; Ellingson KD; Davis K; Cullen T; Brady S; Komatsu KK; Stone ND; Uyeki TM; Slifka KJ; Pérez-Vélez CM; Keaton AA
    J Am Geriatr Soc; 2022 Apr; 70(4):960-967. PubMed ID: 35141874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
    Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
    Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
    Jary A; Marot S; Faycal A; Leon S; Sayon S; Zafilaza K; Ghidaoui E; Quoc SN; Nemlaghi S; Choquet S; Dres M; Pourcher V; Calvez V; Junot H; Marcelin AG; Soulié C
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients.
    Pham DH; Wong S; Nguyen CT; Lee SC; Won KJ
    Healthcare (Basel); 2021 Dec; 10(1):. PubMed ID: 35052205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
    Dhand A; Razonable RR
    Curr Transplant Rep; 2022; 9(1):26-34. PubMed ID: 35070639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real World Utilization of Bamlanivimab at a Rural Community Hospital.
    Leavitt R; Ash J; Hasenbalg P; Santarelli A; Dietrich T; Schritter S; Wells J; Dawson A; Ashurst J
    Cureus; 2021 Nov; 13(11):e19747. PubMed ID: 34938624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities.
    Walker VL; Meyer A; Paauw D; Arend M
    J Am Med Dir Assoc; 2022 Jan; 23(1):141-145. PubMed ID: 34890559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting.
    Corwin DS; Ender PT; Sahu N; Durgham RA; McGorry DM; Rahman A; Stoltzfus J; Jahre JA
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab305. PubMed ID: 34258324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
    Ganesh R; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan P; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
    medRxiv; 2021 May; ():. PubMed ID: 34075387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.